On July 1, 2026, CMS launches the Medicare GLP-1 Bridge — a short-term demonstration providing eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight management. The program runs through December 31, 2027, and operates entirely outside the standard Part D benefit flow. Instead of routing prior authorization through the beneficiary's Part D plan, CMS has contracted with Humana as a single central processor to manage PA, claims adjudication, and pharmacy payment.
This creates a documentation challenge that is different from commercial GLP-1 prior authorization. The clinical criteria are explicit but the supporting evidence requirements — what chart notes, lab results, imaging reports, and medication records the provider must submit — have not yet been fully specified. CMS has stated it will release the PA fax form and submission details in June 2026. Until then, access teams should build evidence files aligned to each criterion.
This article maps every Medicare GLP-1 Bridge clinical criterion to the documentation that supports it. It is written for manufacturer hub teams, provider-office access coordinators, reimbursement specialists, and market access professionals who need to prepare PA submissions for the July 1 launch.
Bridge program overview: what is different
The Medicare GLP-1 Bridge is not a standard Part D benefit. Key structural differences that affect documentation strategy:
| Feature | Standard Part D PA | Medicare GLP-1 Bridge PA |
|---|---|---|
| Processing entity | Part D plan sponsor (PBM) | Central processor (Humana, administering LI NET infrastructure) |
| Submission channel | Plan's PA portal, fax, or ePA | CMS-designated process (form and channel announced June 2026) |
| Plan opt-in required | N/A | No — Part D sponsors do not opt in; Bridge operates independently |
| Copay structure | Plan-specific tier copay | Flat $50 per 30-day supply |
| Covered products | Per plan formulary | Wegovy (injectable and oral), Zepbound KwikPen, Foundayo (oral) |
| Operative dates | Continuous | July 1, 2026 through December 31, 2027 |
| Appeal pathway | Part D plan appeals | Part D appeal rights preserved (Bridge does not alter them) |
CMS confirmed that Part D sponsors will not carry risk for Bridge drugs and cannot block eligible beneficiaries from participating. The Bridge is nationwide and available in all states and territories. Eligible plans include standalone PDPs, Medicare Advantage coordinated care plans with drug coverage (MA-PD), certain Special Needs Plans, and dually eligible beneficiaries. Not eligible: private fee-for-service plans, section 1876 cost contract plans, PACE organizations, fallback plans, and religious fraternal benefit plans — unless the beneficiary is also enrolled in a standalone PDP.
Clinical criteria: the three-tier structure
CMS has defined three BMI-and-comorbidity pathways for Bridge eligibility. The critical detail — and the one most likely to cause documentation failures — is that the clinical criteria are assessed at the time of GLP-1 therapy initiation, not at the time of the PA request. This matters enormously for patients who started GLP-1 therapy before enrolling in Medicare or before the Bridge launch. If a patient began semaglutide in 2024 with a BMI of 37, and now has a BMI of 34, the provider must attest and document the BMI at initiation.
Tier 1: BMI ≥ 35 (no additional conditions required)
The simplest pathway. The provider must document:
- BMI at the time of therapy initiation. A recorded weight and height from the date the patient first received a GLP-1 prescription or the earliest corresponding office visit. If the patient started GLP-1 therapy before the Bridge launch, this may be a historical BMI from a prior chart.
- Current ongoing lifestyle modification. CMS criteria state the beneficiary must be prescribed the drug "to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification including structured nutrition and physical activity." Document referral to or participation in a nutrition program, exercise program, behavioral counseling, or a medically supervised weight management program.
- Age ≥ 18. Straightforward from date of birth.
Evidence file for Tier 1:
| Document | Source | What it proves |
|---|---|---|
| Office visit note with recorded height and weight | Provider EHR | BMI calculation at therapy initiation |
| Weight history or vital signs flow sheet | Provider EHR | Consistent BMI documentation over time |
| Lifestyle modification referral or program enrollment | Provider records, dietician notes | Ongoing structured nutrition and physical activity |
| GLP-1 prescription date and drug name | Pharmacy records, provider notes | Date of therapy initiation |
Tier 2: BMI ≥ 30 with qualifying comorbidity
This tier requires one of three specific comorbidities documented at the time of therapy initiation:
2A. Heart failure with preserved ejection fraction (HFpEF)
HFpEF is a specific diagnosis, not general "heart failure." The provider must document:
- Echocardiogram showing left ventricular ejection fraction ≥ 50%. The echocardiogram report must include the LVEF measurement and date. A narrative note stating "HFpEF" without the echo report is likely insufficient.
- Heart failure diagnosis. ICD-10 code I50.3 (Diastolic [congestive] heart failure) or I50.9 (Heart failure, unspecified), supported by clinical symptoms (dyspnea on exertion, fatigue, orthopnea, peripheral edema), BNP or NT-proBNP elevation, or structural cardiac abnormalities.
- Symptom documentation. Kansas City Cardiomyopathy Questionnaire (KCCQ) score if available, or functional status notes documenting NYHA class.
The STEP-HFpEF trial demonstrated that semaglutide 2.4 mg produced clinically meaningful improvement in heart failure symptoms (KCCQ-CSS score improvement of 16.6 points vs 8.7 for placebo) and 13.3% body weight reduction in patients with HFpEF and obesity, published in the New England Journal of Medicine in 2023. This evidence may support medical-necessity arguments, though CMS has not indicated that trial enrollment or evidence citation is required for Bridge PA.
Evidence file for HFpEF:
| Document | Source | What it proves |
|---|---|---|
| Echocardiogram report with LVEF ≥ 50% | Cardiology records, hospital imaging | HFpEF diagnosis confirmation |
| Heart failure ICD-10 codes | Provider problem list, encounter notes | Formal diagnosis |
| BNP or NT-proBNP lab results | Lab reports | Objective cardiac biomarker evidence |
| Symptom assessment (KCCQ or NYHA class) | Provider notes, cardiology records | Functional impairment |
| Cardiology consultation note (if available) | Specialist records | Specialty confirmation of diagnosis |
2B. Uncontrolled hypertension (despite ≥ 2 antihypertensives)
This criterion is more specific than "hypertension." It requires documentation that blood pressure remains uncontrolled despite concurrent use of at least two antihypertensive medications. The provider must document:
- Hypertension diagnosis. ICD-10 codes I10 (Essential hypertension) or I11.x (Hypertensive heart disease).
- Current antihypertensive regimen. Medication list showing at least two distinct antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, beta-blockers, etc.) with doses and dates prescribed.
- Uncontrolled blood pressure readings. Office blood pressure measurements above guideline targets (typically ≥ 130/80 mmHg per ACC/AHA guidelines) documented on the medication regimen. Multiple readings strengthen the submission.
- Duration of failed control. How long the blood pressure has remained above target despite the dual regimen.
Evidence file for uncontrolled hypertension:
| Document | Source | What it proves |
|---|---|---|
| Office blood pressure readings (multiple visits) | Provider vital signs | Uncontrolled BP despite treatment |
| Current antihypertensive medication list | Provider medication list, pharmacy records | ≥ 2 concurrent agents |
| Hypertension ICD-10 codes | Provider problem list | Formal diagnosis |
| Medication history showing stability of regimen | Pharmacy refill records, provider notes | Adequate trial duration |
2C. Chronic kidney disease stage 3a or above
CKD must be staged at 3a or above (eGFR 15–59 mL/min/1.73 m²). The provider must document:
- eGFR or creatinine lab results. At least one eGFR measurement ≤ 59 mL/min/1.73 m², calculated using the CKD-EPI equation (current standard). A single measurement is clinically accepted for staging, but two measurements ≥ 90 days apart provide stronger evidence of chronicity.
- CKD diagnosis and staging. ICD-10 code N18.3 (Chronic kidney disease, stage 3) or higher.
- Nephrology consultation (if available). While not required by CMS criteria, a nephrology note confirming CKD stage provides supporting evidence.
The FLOW trial (semaglutide in patients with type 2 diabetes and CKD) demonstrated a 24% reduction in major kidney disease events, published in the New England Journal of Medicine in 2024. For patients with both CKD and diabetes, this evidence supports the clinical rationale, though the Bridge criteria do not require diabetes as a precondition for the CKD pathway.
Evidence file for CKD:
| Document | Source | What it proves |
|---|---|---|
| eGFR/creatinine lab results | Lab reports | CKD stage 3a+ (eGFR ≤ 59) |
| Urine albumin-to-creatinine ratio (if available) | Lab reports | Albuminuria supports CKD diagnosis |
| CKD ICD-10 codes with staging | Provider problem list | Formal staged diagnosis |
| Nephrology notes (if available) | Specialist records | Specialty confirmation |
| Prior eGFR measurements showing chronicity | Lab reports | Chronic (not acute) kidney disease |
Tier 3: BMI ≥ 27 with cardiovascular or metabolic diagnosis
This tier requires one of four specific conditions:
3A. Prediabetes (per ADA guidelines)
- HbA1c between 5.7% and 6.4%, or
- Fasting plasma glucose 100–125 mg/dL, or
- 2-hour oral glucose tolerance test 140–199 mg/dL
- Per American Diabetes Association Standards of Care definition
3B. Previous myocardial infarction
- Documented history of MI (ICD-10 code I25.2 or Z86.79)
- Hospital discharge summary, cardiology records, or cardiac biomarker history (troponin elevation)
3C. Previous stroke
- Documented history of ischemic or hemorrhagic stroke (ICD-10 code I63.x or Z86.73)
- Neurology records, hospital discharge summary, or imaging evidence (CT/MRI)
3D. Symptomatic peripheral artery disease
- Documented PAD with claudication symptoms (ICD-10 code I73.9 or I70.x)
- Ankle-brachial index (ABI) < 0.90, or CT/MR angiography showing arterial stenosis, or vascular surgery consultation
Evidence file for Tier 3:
| Document | Source | What it proves |
|---|---|---|
| HbA1c or fasting glucose results | Lab reports | Prediabetes per ADA criteria |
| MI hospital discharge summary | Hospital records | Previous myocardial infarction |
| Stroke imaging or discharge summary | Hospital records, neurology | Previous stroke |
| ABI results or vascular imaging | Vascular lab, radiology | Symptomatic peripheral artery disease |
| Relevant ICD-10 codes | Provider problem list | Formal diagnosis |
The continuation-of-therapy pathway
One of the most important Bridge provisions is the continuation pathway for patients who are already on GLP-1 therapy. CMS has explicitly confirmed that beneficiaries who initiated GLP-1 therapy before enrolling in Medicare Part D or before the July 1, 2026 launch may qualify if they met the clinical criteria at the time they started treatment.
This creates a distinct documentation scenario:
- The provider must document the original BMI and comorbidity status from the date of therapy initiation, even if that was months or years earlier.
- If the patient's BMI has since dropped below the threshold (because the drug worked), this does not disqualify them. CMS's FAQ gives a specific example: "If a beneficiary initiated GLP-1 therapy in September 2024 with a BMI of 37 and has a BMI of 34 at the time of a July 2026 prior authorization request, the prescribing provider should attest that the beneficiary met the BMI ≥ 35 criterion at the time therapy was initiated."
- The provider must also document current ongoing lifestyle modification.
Evidence file for continuation:
| Document | Source | What it proves |
|---|---|---|
| Original BMI record from therapy start | Prior provider records, transferred charts | Eligibility at initiation |
| Original comorbidity documentation from therapy start | Prior records | Met Tier 2 or 3 criteria at initiation |
| Current GLP-1 prescription and dose | Pharmacy records, provider notes | Ongoing active therapy |
| Current lifestyle modification documentation | Provider notes | Ongoing participation |
| Prior authorization from previous insurer (if available) | Prior payer records | Demonstrated prior coverage approval |
Covered drugs and the Foundayo addition
As of the Bridge launch, three products are covered:
| Drug | Active ingredient | Route | FDA-approved weight indication |
|---|---|---|---|
| Wegovy | Semaglutide 0.25–2.4 mg | Subcutaneous injection | Chronic weight management |
| Wegovy oral tablet | Semaglutide 25 mg | Oral | Chronic weight management |
| Zepbound KwikPen | Tirzepatide 2.5–15 mg | Subcutaneous injection | Chronic weight management |
| Foundayo | Orforglipron (oral GLP-1) | Oral | Chronic weight management |
CMS has indicated that additional GLP-1 products — including Ozempic (semaglutide for diabetes), Mounjaro (tirzepatide for diabetes), and Rybelsus (oral semaglutide for diabetes) — will become available under the longer-term BALANCE Model expected to launch after the Bridge period. For the Bridge itself, only products with FDA approval for weight management qualify.
Providers do not need to be enrolled in Medicare to prescribe Bridge-eligible products or submit PA requests.
PA submission mechanics
CMS has confirmed the following process flow:
- Provider prescribes an eligible GLP-1 drug to a beneficiary for a covered use under the demonstration.
- Provider submits the prescription to a pharmacy.
- Pharmacy submits the claim. The claim is routed to the central processor using a specific BIN and PCN number (to be published by CMS).
- Central processor returns a PA request. The provider receives a request to complete prior authorization.
- Provider submits PA request and supporting documentation to the central processor. CMS will provide a fax form and submission instructions in June 2026.
- Central processor adjudicates PA and communicates the decision to the provider and pharmacy.
- If approved, the pharmacy dispenses and collects the $50 copay from the beneficiary. The pharmacy is reimbursed at no less than WAC minus the copay plus a dispensing fee.
PA requests will not be accepted or processed before July 1, 2026. Providers who believe a beneficiary is eligible should prepare the evidence file in advance but wait for the formal process to open.
Common documentation gaps that will cause PA failure
Based on analogous commercial GLP-1 PA processes and CMS's published criteria, the following documentation gaps are most likely to result in denial:
| Gap | Why it causes denial | How to prevent |
|---|---|---|
| BMI recorded at current visit, not at therapy initiation | Does not address the initiation-date requirement | Pull historical weight records from original prescriber |
| "Heart failure" documented without specifying preserved ejection fraction | Does not distinguish HFpEF from HFrEF | Include echocardiogram report showing LVEF ≥ 50% |
| Hypertension listed as diagnosis without documenting uncontrolled status on dual therapy | "Hypertension" alone does not meet the "uncontrolled despite ≥ 2 agents" criterion | Document BP readings above target and concurrent antihypertensive regimen |
| CKD listed without staging or eGFR | Does not confirm stage 3a or above | Include eGFR lab results showing ≤ 59 mL/min/1.73 m² |
| Prediabetes documented without lab values | Clinical impression without ADA-criteria lab confirmation | Include HbA1c or fasting glucose results in the prediabetes range |
| No lifestyle modification documentation | Required criterion per CMS language | Document referral, enrollment, or participation in structured nutrition and physical activity |
| Missing GLP-1 therapy start date | Cannot verify initiation-date criteria | Include prescription records or chart notes from the original prescriber |
What to monitor
- June 2026: CMS will publish the PA fax form and detailed submission instructions on the CMS Medicare GLP-1 Bridge webpage. This will specify the exact documentation requirements, fax number or portal, and attestation language.
- July 1, 2026: PA processing opens. Expect high initial volume and potential processing delays.
- 2027 transition: The Bridge was originally scheduled to end December 31, 2026, and transition to the BALANCE Model on January 1, 2027. CMS has extended the Bridge through December 31, 2027, with the BALANCE Model delayed. Beneficiaries enrolled in the Bridge will need to select a participating Part D plan during 2027 enrollment to maintain coverage.
- Formulary changes: Part D plan sponsors are not responsible for Bridge drugs and should not require formulary exceptions for Bridge-eligible products. If a provider submits a PA to a Part D plan instead of the central processor, the plan should redirect the provider to the central processor.
Sources
- CMS. "Medicare GLP-1 Bridge." Accessed May 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- CMS. "Information for Providers — Medicare GLP-1 Bridge." Accessed May 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
- CMS. "Information for Medicare Beneficiaries." Accessed May 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-medicare-beneficiaries
- CMS. "Information for Pharmacies." Accessed May 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies
- Reed Smith. "Frequently Asked Questions Related to the Medicare GLP-1 Bridge." 2026. https://www.reedsmith.com/media/l3inc0ds/medicare-glp-1-bridge-faqs.pdf
- AMCP. "Regulatory NewsBREAK: CMS Releases FAQs on the Medicare GLP-1 Bridge." 2026. https://www.amcp.org/regulatory-newsbreak-cms-releases-frequently-asked-questions-medicare-glp-1-bridge
- CMS MLN Connects Newsletter, May 7, 2026. https://www.cms.gov/training-education/medicare-learning-network/newsletter/mln-connects-newsletter-may-7-2026
- Kosiborod MN et al. "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity." N Engl J Med. 2023;389(12):1069-1082. (STEP-HFpEF trial)
- Perkovic V et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." N Engl J Med. 2024;391(2):109-121. (FLOW trial)
- Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389(24):2221-2232. (SELECT trial)
Last updated May 31, 2026. This article is for informational purposes only and does not constitute medical advice, reimbursement guidance, or legal counsel. Consult CMS program documents and the Bridge PA form when available for official submission requirements.
